Allison Hoffman Sells 6,585 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison Hoffman sold 6,585 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $112,010.85. Following the completion of the transaction, the general counsel directly owned 174,762 shares in the company, valued at $2,972,701.62. This trade represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Phreesia Price Performance

Shares of PHR stock traded down $0.10 during trading hours on Monday, reaching $17.14. The company had a trading volume of 760,277 shares, compared to its average volume of 1,018,096. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The stock has a fifty day moving average of $18.95 and a 200-day moving average of $23.69. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -171.33 and a beta of 0.61. Phreesia, Inc. has a 12-month low of $15.41 and a 12-month high of $32.76.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.11. The firm had revenue of $120.33 million during the quarter, compared to analysts’ expectations of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The business’s revenue for the quarter was up 12.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.25) earnings per share. On average, equities analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on PHR shares. Citigroup cut their price objective on shares of Phreesia from $29.00 to $25.00 and set a “buy” rating for the company in a research report on Friday. Wells Fargo & Company began coverage on shares of Phreesia in a research note on Thursday. They issued an “overweight” rating and a $30.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phreesia in a research report on Friday, October 31st. Barclays decreased their price objective on Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, December 16th. Finally, JPMorgan Chase & Co. lowered their price objective on Phreesia from $32.00 to $29.00 and set an “overweight” rating for the company in a research report on Tuesday, December 9th. Seventeen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.06.

Institutional Investors Weigh In On Phreesia

A number of hedge funds have recently added to or reduced their stakes in PHR. Squarepoint Ops LLC lifted its holdings in Phreesia by 243.6% during the 2nd quarter. Squarepoint Ops LLC now owns 100,922 shares of the company’s stock worth $2,872,000 after buying an additional 71,553 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Phreesia by 9,375.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock valued at $86,000 after acquiring an additional 3,000 shares during the last quarter. Arcadia Investment Management Corp MI raised its position in shares of Phreesia by 22.3% during the 2nd quarter. Arcadia Investment Management Corp MI now owns 113,470 shares of the company’s stock worth $3,229,000 after acquiring an additional 20,700 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Phreesia by 61.6% during the second quarter. Acadian Asset Management LLC now owns 364,194 shares of the company’s stock worth $10,357,000 after purchasing an additional 138,877 shares during the last quarter. Finally, Boston Partners lifted its stake in Phreesia by 165.1% during the second quarter. Boston Partners now owns 130,060 shares of the company’s stock worth $3,702,000 after purchasing an additional 81,006 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.